| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Silvana Gaetani, Vincenzo Cuomo, Daniele Piomell. Anandamide hydrolysis: a new target for anti-anxiety drugs? Trends in molecular medicine. vol 9. issue 11. 2004-08-12. PMID:14604824. |
the major psychoactive constituent of cannabis, delta(9)-tetrahydrocannabinol, affects emotional states in humans and laboratory animals by activating brain cannabinoid receptors. |
2004-08-12 |
2023-08-12 |
rat |
| Franjo Grotenherme. Pharmacology of cannabinoids. Neuro endocrinology letters. vol 25. issue 1-2. 2004-08-03. PMID:15159677. |
dronabinol (delta 9-tetrahydocannabinol, thc), the main source of the pharmacological effects caused by the use of cannabis, is an agonist to both the cb1 and the cb2 subtype of cannabinoid receptors. |
2004-08-03 |
2023-08-12 |
Not clear |
| Franjo Grotenherme. Pharmacology of cannabinoids. Neuro endocrinology letters. vol 25. issue 1-2. 2004-08-03. PMID:15159677. |
the non-psychotropic cannabidiol (cbd), some analogues of natural cannabinoids and their metabolites, antagonists at the cannabinoid receptors and modulators of the endogenous cannabinoid system are also promising candidates for clinical research and therapeutic uses. |
2004-08-03 |
2023-08-12 |
Not clear |
| Ethan B Russ. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro endocrinology letters. vol 25. issue 1-2. 2004-08-03. PMID:15159679. |
clinical endocannabinoid deficiency (cecd): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? |
2004-08-03 |
2023-08-12 |
Not clear |
| Ethan B Russ. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro endocrinology letters. vol 25. issue 1-2. 2004-08-03. PMID:15159679. |
this study examines the concept of clinical endocannabinoid deficiency (cecd), and the prospect that it could underlie the pathophysiology of migraine, fibromyalgia, irritable bowel syndrome, and other functional conditions alleviated by clinical cannabis. |
2004-08-03 |
2023-08-12 |
Not clear |
| Linda A Parker, Magdalena Kwiatkowska, Page Burton, Raphael Mechoula. Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology. vol 171. issue 2. 2004-07-27. PMID:13680081. |
the principal cannabinoids found in marijuana include the psychoactive compound delta-9-tetrahydrocannabinol (thc) and the non-psychoactive compound cannabidiol (cbd). |
2004-07-27 |
2023-08-12 |
Not clear |
| Gregory T Carter, Patrick Weydt, Muraco Kyashna-Tocha, Donald I Abram. Medicinal cannabis: rational guidelines for dosing. IDrugs : the investigational drugs journal. vol 7. issue 5. 2004-07-21. PMID:15154108. |
cannabinoids, the active ingredients in cannabis, have many distinct pharmacological properties. |
2004-07-21 |
2023-08-12 |
Not clear |
| B Park, H M Gibbons, M D Mitchell, M Glas. Identification of the CB1 cannabinoid receptor and fatty acid amide hydrolase (FAAH) in the human placenta. Placenta. vol 24. issue 10. 2004-07-15. PMID:14580383. |
synthetic cannabinoids, the psychoactive components of the cannabis sativa (marijuana) plant and their endogenous counterparts, act through two g protein-coupled receptors, cb1 and cb2. |
2004-07-15 |
2023-08-12 |
human |
| B Park, H M Gibbons, M D Mitchell, M Glas. Identification of the CB1 cannabinoid receptor and fatty acid amide hydrolase (FAAH) in the human placenta. Placenta. vol 24. issue 10. 2004-07-15. PMID:14580383. |
this is consistent with a placental site of action of endocannabinoids and cannabis being responsible, at least in part, for the poor outcomes associated with cannabis consumption and pathology in the endocannabinoid system during pregnancy. |
2004-07-15 |
2023-08-12 |
human |
| Tri J Raharjo, Wen-Te Chang, Marianne C Verberne, Anja M G Peltenburg-Looman, Huub J M Linthorst, Robert Verpoort. Cloning and over-expression of a cDNA encoding a polyketide synthase from Cannabis sativa. Plant physiology and biochemistry : PPB. vol 42. issue 4. 2004-07-08. PMID:15120113. |
a polyketide synthase has been suggested to play an important role in cannabinoid biosynthesis in cannabis sativa l. this enzyme catalyzes the biosynthesis of olivetolic acid, one of the precursors for cannabinoid biosynthesis. |
2004-07-08 |
2023-08-12 |
Not clear |
| J P Jacques, S Zombek, Ch Guillain, P Due. [Cannabis: experts agree more than they admit]. Revue medicale de Bruxelles. vol 25. issue 2. 2004-06-29. PMID:15157061. |
the psychotropic effects of cannabis--the result of cannabinoids contained in its resin that activate specific receptors--include general euphoria, a mild release from inhibitions and, in certain cases, some distortion of sensory perception. |
2004-06-29 |
2023-08-12 |
human |
| Ruth Gallily, Tal Even-Chena, Galia Katzavian, Dan Lehmann, Arie Dagan, Raphael Mechoula. Gamma-irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells. Leukemia & lymphoma. vol 44. issue 10. 2004-06-21. PMID:14692532. |
gamma-irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured hl-60 myeloblastic leukemia cells. |
2004-06-21 |
2023-08-12 |
human |
| Ruth Gallily, Tal Even-Chena, Galia Katzavian, Dan Lehmann, Arie Dagan, Raphael Mechoula. Gamma-irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells. Leukemia & lymphoma. vol 44. issue 10. 2004-06-21. PMID:14692532. |
two non-psychotropic cannabinoids, cannabidiol (cbd) and cannabidiol-dimethylheptyl (cbd-dmh), induced apoptosis in a human acute myeloid leukemia (aml) hl-60 cell line. |
2004-06-21 |
2023-08-12 |
human |
| Anke Witting, Lisa Walter, Jennifer Wacker, Thomas Möller, Nephi Stell. P2X7 receptors control 2-arachidonoylglycerol production by microglial cells. Proceedings of the National Academy of Sciences of the United States of America. vol 101. issue 9. 2004-06-17. PMID:14976257. |
endogenous cannabinoid ligands (endocannabinoids) produced by neurons, astrocytes, and microglial cells activate cannabinoid receptors, the molecular target for marijuana's bioactive ingredient delta(9)-tetrahydrocannabinol. |
2004-06-17 |
2023-08-12 |
Not clear |
| b' Marta Duran, Joan-Ramon Laporte, Dolors Capell\\xc3\\xa. [News about therapeutic use of Cannabis and endocannabinoid system]. Medicina clinica. vol 122. issue 10. 2004-06-10. PMID:15033046.' |
[news about therapeutic use of cannabis and endocannabinoid system]. |
2004-06-10 |
2023-08-12 |
Not clear |
| Linda A Parker, Raphael Mechoula. Cannabinoid agonists and antagonists modulate lithium-induced conditioned gaping in rats. Integrative physiological and behavioral science : the official journal of the Pavlovian Society. vol 38. issue 2. 2004-06-01. PMID:14527182. |
a series of experiments evaluated the potential of psychoactive cannabinoid agonists, delta-9-thc and hu-210, and non-psychoactive cannabinoids, cannabidiol (cbd) and its dimethylheptyl homolog (cbd-dmh), to interfere with the establishment and the expression of conditioned gaping in rats. |
2004-06-01 |
2023-08-12 |
rat |
| Emmanuel Contassot, Mirna Tenan, Valérie Schnüriger, Marie-Françoise Pelte, Pierre-Yves Dietric. Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1. Gynecologic oncology. vol 93. issue 1. 2004-05-20. PMID:15047233. |
delta(9)-tetrahydrocannabinol, the active agent of cannabis sativa, exhibits well-documented antitumor properties, but little is known about the possible effects mediated by endogenous cannabinoids on human tumors. |
2004-05-20 |
2023-08-12 |
human |
| P J McLaughlin, K Winston, L Swezey, A Wisniecki, J Aberman, D J Tardif, A J Betz, K Ishiwari, A Makriyannis, J D Salamon. The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behavioural pharmacology. vol 14. issue 8. 2004-05-19. PMID:14665975. |
cannabinoid cb1 receptor agonists, including delta-9-tetrahydrocannabinol (delta 9-thc) (the main psychoactive ingredient in marijuana) have been shown to increase feeding in rats and humans. |
2004-05-19 |
2023-08-12 |
rat |
| C Robin Hiley, William R For. Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling. Biological reviews of the Cambridge Philosophical Society. vol 79. issue 1. 2004-05-19. PMID:15005177. |
cannabinoids include not only plant-derived compounds (of which delta9-tetrahydrocannabinol is the primary psychoactive ingredient of cannabis), but also synthetic agents and endogenous substances termed endocannabinoids which include anandamide (2-arachidonoylethanolamide) and 2-arachidonoylglycerol. |
2004-05-19 |
2023-08-12 |
human |
| María G Sánchez, Lidia Ruiz-Llorente, Ana M Sánchez, Inés Díaz-Laviad. Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cellular signalling. vol 15. issue 9. 2004-05-05. PMID:12834810. |
treatment of pc-3 cells with either delta(9)-tetrahydrocannabinol (thc), the major psychoactive ingredient of marijuana, or r-(+)-methanandamide (met), an analogue of the endogenous cannabinoid anandamide, increased phosphorylation of pkb in thr308 and ser473. |
2004-05-05 |
2023-08-12 |
human |